Biopharma Startup Accelerates Time-to-Market by 30% with Absolute Zero’s GMP-Compliant Lyophilizer
- Overview
- Recommended Products
Customer
Vectura Biologics, a U.S.-based biopharmaceutical startup developing novel antibody-drug conjugates.
The Challenge
Vectura Biologics had a promising drug candidate but faced a major bottleneck: lyophilization (freeze-drying). Their existing lab-scale equipment was not GMP-compliant, and they were struggling with inconsistent batch quality and a lack of proper documentation for their FDA submission. They needed a production-scale lyophilizer that could not only deliver a high-quality, stable product but also provide the data integrity and validation support required to navigate the stringent regulatory approval process.
The Solution
Absolute Zero was selected as a partner due to our deep expertise in pharmaceutical applications. We provided a turnkey solution centered around the AZ-LY 10m² Pharmaceutical Lyophilizer.
•Full GMP/FDA Compliance: The unit was designed from the ground up to meet regulatory requirements, featuring 316L stainless steel, CIP/SIP systems, and a control system compliant with FDA 21 CFR Part 11.
•Process Optimization Support: Our technical team worked closely with Vectura’s scientists to transfer their process from the lab to the production scale, developing an optimized and validated freeze-drying cycle.
•Comprehensive Validation Package: We provided a complete IQ/OQ/PQ documentation package, saving Vectura’s small team hundreds of hours of work and providing a clear path for regulatory submission.
The Results
The impact on Vectura’s operations was immediate and profound:
•30% Faster Time-to-Market: The streamlined validation process and reliable performance of the AZ-LY unit allowed Vectura to complete their process validation and submit their drug application 30% faster than projected.
•Achieved Batch Consistency: The precise temperature and vacuum control of the lyophilizer resulted in a batch-to-batch product consistency of over 99%, a critical factor for FDA approval.
•Passed Regulatory Audits: With the robust data integrity and validation documentation, Vectura passed their pre-approval inspection with no observations related to the lyophilization process.
•Reduced Cycle Time by 18%: Our process optimization support helped them refine their freeze-drying cycle, reducing the total time by 18% and increasing their production throughput.
“Choosing Absolute Zero was the best decision we made in our scale-up process. Their lyophilizer is a brilliant piece of engineering, but it was their expertise in GMP compliance and process validation that was truly invaluable. They weren’t just a vendor; they were a genuine partner in our success.”— Dr. Aris Thorne, Chief Scientific Officer, Vectura Biologics
